IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

P. Lippens et al.

Attorney Docket No.: CASM116373

Application No.: 09/673,428

Group Art Unit: 3722

Filed:

December 5, 2000

Examiner: --

Title:

URITY ELEMENT TO PREVENT COUNTERFEITING OF VALUE CUMENTS

INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

February 14, 2001

TO THE COMMISSIONER FOR PATENTS:

Applicants are aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1. Copies of the listed patents, publications, and other information are enclosed for __X the Examiner's use.

Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being 2. $_{\mathsf{L}}$ X filed within three months of the filing date of the national application (other than a CPA), within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, before the mailing date of a first Office Action on the merits, or before the mailing date of a first Office Action after the filing of an RCE.

III

III

III

111

III

 $\parallel \parallel$

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESSPLLE 1420 Fifth Avenue **Suite 2800** Seattle, Washington 98101 206.682.8100

3. X The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 03-1740. This authorization also hereby includes a request for any extensions of time of the appropriate length required upon the filing of any reply during the entire prosecution of this application. A copy of this document is enclosed.

Respectfully submitted,

CHRISTENSEN O'CONNOR JOHNSON KINDNESSPJC

Gary S. Kindness

Registration No. 22,178 Direct Dial No. 206.695,1702

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to the Commissioner for Patents, Washington, D.C. 20231, on the below date.

Date:

February 14, 2001

GSK/PAS:lsj